Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
Current Oncology (Toronto, Ont.)
|
September 27, 2023
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
Jan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, et al.
The Breast Journal
|
July 3, 2014
Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact
Daniel Rayson, Sarah Lutes, Gordon Walsh, et al.
The Oncologist
|
November 12, 2013
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer
Sunil Verma, Anil A Joy, Daniel Rayson, et al.
Journal of Cutaneous Pathology
|
June 21, 2021
Independent primary cutaneous and mammary apocrine carcinomas with neuroendocrine differentiation: Report of a case and literature review
Ryan C DeCoste, Michael D Carter, Penelope J Barnes, et al.
Histopathology
|
April 28, 2015
Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization
Gillian C Bethune, Daniel Veldhuijzen van Zanten, Rebecca F MacIntosh, et al.
Current Oncology (Toronto, Ont.)
|
December 22, 2022
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
Daniel Rayson, Sonal Gandhi, Anil A Joy, et al.
Clinical Colorectal Cancer
|
July 31, 2016
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid
Michael Yan, Cheryl Ho, Eric Winquist, et al.
Current Oncology (Toronto, Ont.)
|
March 28, 2023
Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review
Margaret Sheridan, Bruce Colwell, Nathan W D Lamond, et al.
Current Oncology (Toronto, Ont.)
|
May 26, 2023
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895"
Daniel Rayson, Sonal Gandhi, Anil A Joy, et al.
Clinical Colorectal Cancer
|
October 14, 2018
ACTH-Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature
Ahmed Mokhtar, Thomas Arnason, Daniel Gaston, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
Current Oncology (Toronto, Ont.)
|
September 27, 2023
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
Jan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, et al.
The Breast Journal
|
July 3, 2014
Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact
Daniel Rayson, Sarah Lutes, Gordon Walsh, et al.
The Oncologist
|
November 12, 2013
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer
Sunil Verma, Anil A Joy, Daniel Rayson, et al.
Journal of Cutaneous Pathology
|
June 21, 2021
Independent primary cutaneous and mammary apocrine carcinomas with neuroendocrine differentiation: Report of a case and literature review
Ryan C DeCoste, Michael D Carter, Penelope J Barnes, et al.
Histopathology
|
April 28, 2015
Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization
Gillian C Bethune, Daniel Veldhuijzen van Zanten, Rebecca F MacIntosh, et al.
Current Oncology (Toronto, Ont.)
|
December 22, 2022
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
Daniel Rayson, Sonal Gandhi, Anil A Joy, et al.
Clinical Colorectal Cancer
|
July 31, 2016
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid
Michael Yan, Cheryl Ho, Eric Winquist, et al.
Current Oncology (Toronto, Ont.)
|
March 28, 2023
Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review
Margaret Sheridan, Bruce Colwell, Nathan W D Lamond, et al.
Current Oncology (Toronto, Ont.)
|
May 26, 2023
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895"
Daniel Rayson, Sonal Gandhi, Anil A Joy, et al.
Clinical Colorectal Cancer
|
October 14, 2018
ACTH-Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature
Ahmed Mokhtar, Thomas Arnason, Daniel Gaston, et al.
Page
of 9